Rocket Pharmaceuticals, Inc. (RCKT) SEC Filings & Earnings Calls

Clinical trial risks remain, including safety findings and enrollment challenges.

“Forward-looking statements caution about clinical trial results, safety findings, and ability to enroll patients.”

Clinical trial risk remains; only 3 of 12 patients dosed, with no efficacy data yet.

“first three patients treated under the modified protocol... All three completed at least four weeks of follow-up” · word for word

Clinical and regulatory risks remain for pipeline programs, including Danon disease, PKP2-ACM, and BAG3-DCM. Commercial execution risk for KRESLADI in ultra-rare population.

“Rocket is actively engaging with the FDA to seek alignment on the path to dosing additional patients and completing the pivotal Phase 2 trial. ... Focused commercialization strategy calibrated to the ultra-rare patient population.” · word for word

Clinical trial safety risk

“In May 2025, two patients participating in the Phase 2 pivotal study of RP-A501 each experienced an unexpected SAE. The SAEs involved clinical complications related to a capillary leak syndrome resulting in multi-organ damage; one patient died as a result of these complications following an acute systemic infection.” · word for word

No product revenue yet

“We have not generated revenue from product sales to date. KRESLADI™ was approved by the FDA in March 2026 under the accelerated approval pathway; however, given the ultra-rare patient population and anticipated phased commercial rollout, we do not expect KRESLADI™ to generate material revenue in the near term.” · word for word

Dependence on additional financing

“In the longer term, our future viability is dependent on our ability to generate cash from operating activities or to raise additional capital to finance our operations.” · word for word

Regulatory approval uncertainty for pipeline

“We may never succeed in achieving regulatory approval for any of our product candidates.” · word for word

Regulatory pathway still uncertain; FDA alignment pending.

“Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update expected in the second half of 2026.” · word for word

Dependence on PRV monetization for near-term liquidity; no recurring revenue from this source.

“PRV sale is a one-time event; company remains pre-revenue from product sales.”

Clinical trial risk

“In May 2025, two patients participating in the Phase 2 pivotal study of RP-A501 each experienced an unexpected SAE. The SAEs involved clinical complications related to a capillary leak syndrome resulting in multi-organ damage; one patient died as a result of these complications following an acute systemic infection.” · word for word

No product revenue

“We have not generated revenue from product sales to date.” · word for word

Accumulated deficit

“we had an accumulated deficit of $1.49 billion” · word for word

Dependence on future financing

“Our future viability is dependent on our ability to generate cash from operating activities or to raise additional capital to finance our operations.” · word for word

Pre-commercial biotech with no product revenue; reliance on pipeline and partnerships

“No revenue reported; net loss of $47.6M; cash runway extended but still negative cash flow”

Transaction subject to HSR clearance and other closing conditions; failure to close could impact cash runway.

“The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.”

Stock price decline erodes option incentive value

“Since February 2021, when our stock closed as high as $65.91 (on February 8, 2021), declines in our stock price have eroded the retentive and incentive value of stock options granted.” · word for word

Clinical and regulatory risk for pipeline

“We have deprioritized further development activities related to our Fanconi Anemia and Pyruvate Kinase Deficiency programs.” · word for word

Approval is under accelerated approval based on biomarker endpoints; continued approval contingent on confirmatory trial results.

“This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression. Confirmation of clinical benefit will be based on the evaluation of longer-term follow-up data” · word for word

Potential dilution from ATM offering; may indicate cash burn or need for capital.

“Up to $100M common stock offering; termination of prior ATM agreement.”

Clinical hold and SAEs in pivotal trial

“In May 2025, two patients participating in the Phase 2 pivotal study of RP-A501 each experienced an unexpected SAE. The SAEs involved clinical complications related to a capillary leak syndrome resulting in multi-organ damage; one patient died as a result of these complications following an acute systemic infection. Rocket voluntarily paused further Phase 2 ” · word for word

Dose reduction may impact efficacy

“The FDA authorized resumption of the Phase 2 pivotal study with a recalibrated dose of 3.8 x 10¹³ GC/kg of RP-A501.” · word for word

Cash runway and need for additional funding

“We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce, or eliminate our product development programs or commercial development efforts.” · word for word

Clinical trial execution risk; Phase 2 Danon trial resumption and FDA alignment needed.

“Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026; FDA alignment required after three patients.” · word for word

Regulatory approval risk for KRESLADI; PDUFA date March 2026.

“KRESLADI for severe LAD-I on track for March 28, 2026 PDUFA date.” · word for word

Clinical hold and safety risk for lead program RP-A501

“In May 2025, two patients participating in the Phase 2 pivotal study of RP-A501 each experienced an unexpected SAE. The SAEs involved clinical complications related to a capillary leak syndrome and were followed by a systemic infection and multi-organ damage, ultimately leading to one of the patient’s death. Rocket voluntarily paused further Phase 2 study do” · word for word

Pipeline concentration and program de-prioritization

“the Company is no longer allocating additional internal resources towards regulatory filings and commercial activities for RP-L102 and subsequently is no longer pursuing BLA and EMA submissions for RP-L102.” · word for word

No approved products or revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Dependence on additional financing

“Our future viability is dependent on our ability to generate cash from operating activities or to raise additional capital to finance our operations.” · word for word

Clinical and regulatory risk for pipeline assets; no approved products yet.

“RP-A501 pivotal trial to resume in 1H 2026; KRESLADI PDUFA March 2026; no revenue.”